Microtubule assembly by tau impairs endocytosis and neurotransmission via dynamin sequestration in Alzheimer’s disease synapse model

Tetsuya Hori1,2, Kohgaku Eguchi1,3, Han-Ying Wang1, Tomohiro Miyasaka2, Laurent Guillaud1,4, Zacharie Taoufiq1, Satyajit Mahapatra1, Hiroshi Yamada5, Kohji Takei5, Tomoyuki Tahash1*

1Cellular and Molecular Synaptic Function Unit, Okinawa Institute of Science and Technology - Graduate University, Okinawa, Japan; 2Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan; 3Institute of Science and Technology Austria (IST Austria), Klosterneuburg, Austria; 4Molecular Neuroscience Unit, Okinawa Institute of Science and Technology Graduate University, Okinawa, Japan; 5Department of Neuroscience, Graduate school of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan

Abstract Elevation of soluble wild-type (WT) tau occurs in synaptic compartments in Alzheimer’s disease. We addressed whether tau elevation affects synaptic transmission at the calyx of Held in slices from mice brainstem. Whole-cell loading of WT human tau (h-tau) in presynaptic terminals at 10–20 µM caused microtubule (MT) assembly and activity-dependent rundown of excitatory neurotransmission. Capacitance measurements revealed that the primary target of WT h-tau is vesicle endocytosis. Blocking MT assembly using nocodazole prevented tau-induced impairments of endocytosis. Immunofluorescence imaging analyses revealed that MT assembly by WT h-tau loading was associated with an increased MT-bound fraction of the endocytic protein dynamin. A synthetic dodecapeptide corresponding to dynamin 1-pleckstrin-homology domain inhibited MT-dynamin interaction and rescued tau-induced impairments of endocytosis and neurotransmission. We conclude that elevation of presynaptic WT tau induces de novo assembly of MTs, thereby sequestering free dynamins. As a result, endocytosis and subsequent vesicle replenishment are impaired, causing activity-dependent rundown of neurotransmission.

Editor's evaluation
This study provides an interesting new insight into the synaptic disease mechanisms of tauopathies. The paper is based on a technically very rigorous dataset indicating that increased levels of soluble Tau impair pre-synaptic endocytosis and, consequently, neurotransmission by sequestering Dynamin-1 on microtubules. The findings are of major relevance for basic neuronal cell biology and translational neuroscience alike.

Introduction
The microtubule (MT)-binding protein tau assembles and stabilizes MTs (Brunden et al., 2009; Lee et al., 2011) mainly in axonal compartments (Binder et al., 1985; Kubo et al., 2019). Phosphorylation of tau proteins reduces their binding affinity (Biernat et al., 1993; Drechsel et al., 1992), thereby
shifting the equilibrium from MT-bound form to soluble free form (Ballatore et al., 2007). Soluble tau proteins also exist in dynamic equilibrium between phosphorylated and dephosphorylated forms (Spillantini and Goedert, 2013) as well as between soluble and aggregated forms. When the cytosolic tau concentration is elevated, monomeric tau undergoes oligomerization and eventually precipitates into neurofibrillary tangles (NFT) (Greenberg and Davies, 1990; Grundke-Iqbal et al., 1986; Yoshida and Ihara, 1993), which is a hallmark of tauopathies, including Alzheimer’s disease (AD), frontotemporal dementia with Parkinsonism-17 (FTDP-17), and progressive supranuclear palsy (Lee et al., 2011; Ballatore et al., 2007; Spillantini and Goedert, 2013). Although the NFT density can correlate with the degree of AD progression (Lee et al., 2011; Ballatore et al., 2007; Morris et al., 2011), soluble tau protein levels are more closely linked to disease progression and cognitive decline (Götz et al., 2008; Koss et al., 2016).

Genetic ablation of tau shows little abnormal phenotype (Harada et al., 1994; Vossel et al., 2010; Yuan et al., 2008), presumably due to compensation by other MT-associated proteins (Harada et al., 1994). Instead, tau ablation can prevent amyloid β-induced impairments of mitochondrial transport (Vossel et al., 2010) or memory defects (Ittner et al., 2010; Roberson et al., 2007). Thus, loss of tau function due to its dissociation from MTs is unlikely to be an important cause of neuronal dysfunction in AD (Spillantini and Goedert, 2013; Morris et al., 2011).

In postmortem brains of both AD patients and intact humans, tau is present in synaptosomes (Fein et al., 2008; Tai et al., 2012). In a transgenic mice AD model, soluble tau is accumulated in the hippocampal nerve terminal zone (de Calignon et al., 2012; Liu et al., 2012). Both in in vivo and in culture models of tauopathy, tau is released from axon terminals upon KCl stimulation in a Ca2+-dependent manner, like neurotransmitters (Pooler et al., 2013; Yamada et al., 2014). Tau oligomers produced by released tau triggers endogenous tau seeding in neighboring neurons, thereby causing trans-synaptic propagations (de Calignon et al., 2012; Guo and Lee, 2011).

FTDP tauopathy model mice that overexpressed with mutant tau are widely used to examine tau toxicities on synaptic plasticity (Polydoro et al., 2014; Sydow et al., 2011; Yoshiyama et al., 2007), memory formation (Sydow et al., 2011; Santacruz et al., 2005), as well as on synaptic vesicle (SV) transport (McInnes et al., 2018; Zhou et al., 2017). In contrast to FTDP, which is a rare familial disease associated with tau mutation, AD is a widespread sporadic disease unassociated with tau mutation, but the expression level of WT tau being crucial. As AD models, the effects of WT tau overexpression have been examined in culture cells (Ebnet et al., 1998; Shahpasand et al., 2012; Stamer et al., 2002; Thies and Mandelkow, 2007) or in Drosophila (Mudher et al., 2004), where impaired axonal transports associated with increased MT density were found. These observations suggest that WT tau can be detrimental when its levels are elevated (Stamer et al., 2002; Thies and Mandelkow, 2007). However, unlike FTDP tau mutant, it is unknown whether elevated soluble WT tau can affect mammalian central synaptic transmission.

We addressed this question using the giant nerve terminal calyx of Held visualized in slices from mice brainstem, where axonal MTs extended into the depth of terminals (Piriya Ananda Babu et al., 2020). In this presynaptic terminal, we loaded recombinant WT h-tau from a whole-cell patch pipette at fixed concentrations to model the elevation of WT tau associated with AD and found that WT h-tau newly assembled MTs and strongly impaired synaptic transmission. Capacitance measurements indicated that the primary target of WT h-tau is vesicle endocytosis. Immunocytochemical image analysis after cell permeabilization revealed an increase in the MT-bound fraction of the endocytic GTPase dynamin in WT h-tau-loaded terminals. Since the endocytic key protein dynamin is an MT-binding protein (Shpetner and Vallee, 1989), dynamin is likely sequestered by newly assembled MTs. Out of screening, we found that a synthetic dodecapeptide corresponding to amino acids 560–571 of dynamin 1 inhibited MT-dynamin interaction. When we co-loaded this peptide ‘PHDPS’ with WT h-tau, its toxicities on vesicle endocytosis as well as on synaptic transmission were rescued. Thus, we propose a novel synaptic dysfunction mechanism underlying AD, in which WT tau-induced over-assembly of MTs depletes dynamins, thereby impairs vesicle endocytosis and synaptic transmission.
Results

Intra-terminal loading of WT h-tau impairs excitatory synaptic transmission

To address whether elevation of soluble h-tau in presynaptic terminals can affect synaptic transmission, we purified WT recombinant h-tau (0N4R) and its deletion mutant (del-MTBD) lacking the MT-binding site (244Gln–367Gly) (Figure 1—figure supplement 1A), obtained using an Escherichia coli expression system (Xie et al., 2014). These recombinant h-tau proteins are highly soluble at room temperature (RT) without any sign of granulation (Maeda et al., 2007). In simultaneous pre- and postsynaptic recording at the calyx of Held in mouse brainstem slices, we recorded EPSCs evoked at 1 Hz by presynaptic action potentials (Figure 1). After confirming stable EPSC amplitude for 10 min, we injected a large volume of internal solution containing WT h-tau (20 µM) from an installed fine tube to a presynaptic whole-cell pipette to replace most of pipette solution and allow h-tau to diffuse into a presynaptic terminal (illustration in Figure 1A; Hori et al., 1999; Takahashi et al., 2012). After loading h-tau (20 µM), the amplitude of glutamatergic EPSCs gradually declined and reached 23% ± 9% in 30 min (Figure 1A, p < 0.01, paired t-test, n = 6 synapses in 6 slices). WT h-tau loaded at a lower concentration (10 µM) caused a slower EPSC rundown to 65% ± 5% in 30 min (p < 0.01, n = 5 synapses in 5 slices). Del-MTBD (20 µM), lacking tubulin polymerization capability (Figure 1—figure supplement 1B), likewise loaded had no effect on EPSC amplitude (Figure 1A). Since h-tau concentrations in presynaptic terminals are equilibrated with those in a presynaptic whole-cell pipette with a much greater volume than terminals (Pusch and Neher, 1988), these results suggest that WT h-tau >10 µM can significantly impair excitatory synaptic transmission.

The inhibitory effect of WT h-tau on EPSCs was apparently frequency-dependent. When evoked at 0.1 Hz, WT h-tau (20 µM) caused only a minor reduction of EPSC amplitude (to 85% ± 12%, 30 min after loading, p = 0.21, n = 5; Figure 1B). Since taxol shares a common binding site of MTs with tau (Kar et al., 2003) and assembles tubulins into MTs (Figure 1—figure supplement 1B), we tested the effect of taxol (1 µM) on EPSCs (Figure 1C). Like h-tau, taxol caused a significant rundown of EPSCs evoked at 1 Hz (to 41 ± 12 at 30 min, n = 5, p < 0.05), but not those evoked at 0.1 Hz (104% ± 3.0%, n = 4, p = 0.60). These results together suggest that MTs newly assembled in presynaptic terminals by WT h-tau or taxol cause activity-dependent rundown of excitatory synaptic transmission.

WT h-tau primarily inhibits SV endocytosis and secondarily exocytosis

To determine the primary target of h-tau causing synaptic dysfunction, we performed membrane capacitance measurements at the calyx of Held (Eguchi et al., 2017; Sun and Wu, 2001; Wang et al., 2020; Yamashita et al., 2005). Since stray capacitance of perfusion pipettes prevents capacitance measurements, we backfilled h-tau into a conventional patch pipette after preloading normal internal solution only at its tip to secure GΩ seal formation. This caused substantial and variable delays of the intra-terminal diffusion, so no clear effect could be seen more than 10 min after whole-cell patch membrane was ruptured. Twenty minutes after whole-cell patch loading of WT h-tau (20 µM), endocytic capacitance showed a significant slowing (Figure 2), whereas exocytic capacitance magnitude (ΔCm) or charge of Ca²⁺ currents (QCa) induced by a depolarizing pulse was not different from controls without h-tau loading. Thirty minutes after loading h-tau, the endocytic capacitance change became further slowed (p < 0.01), and exocytic ΔCm eventually showed a significant reduction (p < 0.05, n = 5) without a change in QCa. These results suggest that the primary target of h-tau toxicity is SV endocytosis. Endocytic block inhibits recycling replenishment of SVs via recycling, thereby reducing the exocytic release of neurotransmitter as a secondary effect.

Inhibition of SV endocytosis and synaptic transmission by WT h-tau requires de novo MT assembly

Since new MT assembly might take place after h-tau loading (Figure 1, Figure 1—figure supplement 1), we tested whether the tubulin polymerization blocker nocodazole might reverse the toxic effects of h-tau on SV endocytosis and synaptic transmission. In tubulin polymerization assays, nocodazole inhibited h-tau-dependent MT assembly in a concentration-dependent manner, with a maximal inhibition reached at 20 µM (Figure 3A). In presynaptic capacitance measurements, nocodazole (20 µM) co-loaded with h-tau (20 µM) fully prevented the h-tau toxicities on endocytosis (Figure 3B) and
Figure 1. Wild-type (WT) human tau (h-tau) loaded in presynaptic terminals inhibited excitatory synaptic transmission. (A) In simultaneous pre- and postsynaptic whole-cell recordings, intra-terminal infusion of WT h-tau at 10 µM (blue filled circles) or 20 µM (black filled circles), from a tube in a presynaptic patch pipette (top illustration), caused a concentration-dependent rundown of EPSCs evoked by presynaptic action potentials at 1 Hz. In the time plots, EPSC amplitudes averaged from 60 events are sampled for data points and normalized to the mean amplitude of baseline EPSCs before

Figure 1 continued on next page
h-tau infusion. Sample records of EPSCs 5 min before (i) and 30 min after (ii) tau infusion are superimposed and shown on the left panels. The EPSC amplitude remaining 30 min after infusion was 23% ± 9% and 65% ± 5%, respectively, for 10 and 20 µM h-tau (means and SEMs, 6 synapses from 6 slices, p < 0.01 in paired t-test between before and after h-tau infusion). Infusion of microtubule (MT)-binding site-deleted h-tau mutant (del-MTBD, 20 µM, Figure 1—figure supplement 1A) had no effect on the EPSC amplitude (open circles, sample EPSC traces shown on the left bottom panel). (B) The amplitude of EPSCs evoked at 0.1 Hz remained unchanged after h-tau infusion (85% ± 12%, 5 synapses from 5 slices, p = 0.22 in paired t-test). Sample records of EPSCs before (i) and 30 min after (ii) h-tau infusion at 0.1 Hz are superimposed on the left panel. (C) Taxol (1 µM) caused activity-dependent rundown of EPSC amplitude to 41.4% ± 12% at 1 Hz (p < 0.01, 5 synapses from 5 slices), but remained unchanged when stimulated at 0.1 Hz (105% ± 3.0%, open circles, 4 synapses from 4 slices). Sample records of EPSCs at 0.1 and 1 Hz are superimposed on the left panels.

The online version of this article includes the following source data and figure supplement(s) for figure 1:

**Source data 1.** Wild-type (WT) h-tau loaded in presynaptic terminals inhibited excitatory synaptic transmission.

**Figure supplement 1.** Tubulin polymerization assay for purified 0N4R wild-type (WT) human tau (h-tau) and microtubule (MT)-binding region-deleted mutant.

**Figure supplement 1—source data 1.** Raw SDS-PAGE gel data from Figure 1—figure supplement 1A.

**Figure supplement 1—source data 2.** Data from Figure 1—figure supplement 1B.

WT h-tau assembles MTs and sequesters dynamins in calyceal terminals

The monomeric GTPases dynamins 1 and 3 play critical roles in the endocytic fission of SVs (Hinshaw and Schmid, 1995; Raimondi et al., 2011; Takei et al., 1995). Since dynamin is originally discovered as an MT-binding protein (Shpeter and Vallee, 1989), we hypothesized that newly assembled MTs might trap free dynamin in cytosol. If this is the case, MT-bound form of dynamin would be increased. To test this hypothesis, we performed immunofluorescence microscopy and image analysis to quantify MTs and dynamin. After whole-cell infusion of h-tau into calyceal terminals, slices were chemically fixed and permeabilized to allow cytosolic-free molecules such as tubulin monomers to be washed out of the terminal, thereby enhancing the signals from large structures such as MTs or MT-bound molecules. Fluorescent h-tau antibody identified calyceal terminals loaded with WT h-tau (20 µM, Figure 4A). Double staining with mouse β3-tubulin antibody revealed a 2.1-fold increase in MT signals in h-tau-loaded terminals, compared with those without h-tau loading (p = 0.01, n = 5, two-tailed unpaired t-test). Further increase of dynamin antibodies was observed in h-tau-loaded terminals (p = 0.01, n = 5, two-tailed unpaired t-test with Welch’s correction, Figure 4B). Triple labeling with dynamin antibodies further revealed a 2.6-fold increase in dynamin signal (p = 0.01, n = 5, two-tailed unpaired t-test with Welch’s correction, Figure 4B). In super-resolution imaging, dynamins are shown in clusters along MTs in tau-loaded calyceal terminal (Figure 4—figure supplement 1). These results suggest that soluble WT h-tau can assemble MTs in presynaptic terminals, thereby sequestering cytosolic dynamins that are indispensable for SV endocytosis.

Besides dynamins, MTs can bind to various other proteins. Among them, formin mDia can bind to MTs (Bartolini and Gundersen, 2010) and involved in the endocytic scaffold functions together with F-actin, intersectin, and endophilin. Although acute depolymerization of F-actin (Piriya Ananda Babu et al., 2020; Eguchi et al., 2017) or genetic ablation of intersectin (Sakaba et al., 2013) has no effect on SV endocytosis at the calyx of Held, the formin mDia inhibitor SMFH2 reportedly inhibits endocytosis at the calyx terminals in pre-hearing rats (postnatal days [P] 8–12) (Soykan et al., 2017). We re-examined whether the drug might inhibit SV endocytosis at calyceal terminals in slices from post-hearing mice (P13–14). SMFH2 slightly prolonged SV endocytosis, but this effect was statistically insignificant (Figure 4—figure supplement 2A). Thus, formin unlikely makes substantial contribution to the marked endocytic slowing observed after intra-terminal tau loading (Figure 2).

It may also be argued that binding of endophilin to MTs (Schuske et al., 2003) might cause EPSC rundown since endophilin is involved in clathrin uncoating (Watanabe et al., 2018), which is required for SV refilling with glutamate. If SV refilling during recycling is impaired, miniature EPSCs are decreased in amplitude and frequency (Takami et al., 2017). However, neither amplitude nor frequency was affected by intra-terminal loading of tau (20 µM) (Figure 4—figure supplement 2B). Thus, endophilin-MT binding unlikely underlies EPSC rundown by intra-terminal tau infusion (Figure 1).
An MT-dynamin-binding inhibitor peptide attenuates h-tau toxicities on SV endocytosis and synaptic transmission

To prevent toxic effects of h-tau on endocytosis and transmission, we searched for a dominant-negative (DN) peptide blocking MT-dynamin binding. Since the MT-binding domain of dynamins is unknown, we synthesized 11 peptides from the pleckstrin-homology (PH) domain and 11 peptides from the proline-rich domain of dynamin 1 (Figure 4—figure supplement 1A) and submitted them to the MT-dynamin 1-binding assay. Out of 22 peptides, one peptide corresponding to the amino acid sequence 560–571 of PH domain, which we named ‘PHDP5’, significantly inhibited the MT-dynamin 1 interaction (Figure 5, Figure 5—figure supplement 1B and C). By SYPRO orange staining, dynamin 1 is found as an ~100 kDa band, 1.7% ± 0.4% in precipitates (ppts). In the presence of MT, dynamin 1
Figure 3. The microtubule (MT) assembly blocker nocodazole prevented tau-induced block of synaptic vesicle (SV) endocytosis and EPSC rundown. (A) Concentration-dependent inhibitory effects of nocodazole on MT assembly in tubulin polymerization assay. MT assembly by 0N4R human tau (h-tau) (20 µM) in the absence (pink symbols and a fitting line) or presence of nocodazole at 1 µM (blue), 10 µM (red), 20 µM (purple), and 50 µM (orange). Data points and error bars in all graphs represent means and SEMs (n = 3). (B) Nocodazole prevented h-tau-induced block of SV endocytosis. Presynaptic membrane capacitance changes (superimposed traces) 25 min after loading h-tau alone (20 µM, red trace), h-tau and nocodazole (20 µM, blue), nocodazole alone (20 µM, green), and controls with no loading (black). Bar graphs indicate endocytic rates in non-loading controls (Ctr, black, \( \delta \))
terminals from 6 slices), h-tau-loaded terminals (Tau, red, 8 terminals from 8 slices), co-loading of nocodazole with h-tau (N + T, blue, 7 terminals from 7 slices), and nocodazole alone (Noc, green, 8 terminals from 8 slices). Nocodazole co-loading fully prevented endocytic block by h-tau (**p < 0.01, between Tau and N-T) to control level (one-way ANOVA with Scheffe post hoc test). (C) Nocodazole prevented EPSC rundown caused by wild-type (WT) h-tau. Nocodazole (20 µM) co-loaded with WT h-tau (20 µM) prevented EPSC rundown (filled circles, 4 synapses from 4 slices, **p < 0.01, unpaired t-test). Data of WT h-tau effect on EPSCs (Figure 1A) is shown as a red dashed line for comparison. Nocodazole alone (20 µM) had no effect on EPSC amplitude throughout (open circles, 4 synapses from 4 slices).

The online version of this article includes the following source data for figure 3:

Source data 1. The microtubule (MT) assembly blocker nocodazole prevented tau-induced block of synaptic vesicle (SV) endocytosis and EPSC rundown.

in ppts increased to 22.6% ± 2.4%, indicating sequestration of dynamin 1 by MTs. When PHDP5 was added to MT and dynamin 1, dynamin 1 in the ppt fraction decreased to 6.3% ± 2.4%, indicating that PHDP5 works as a DN peptide for inhibiting MT-dynamin interactions (Figure 5A).

A cryo-electron microscope study on dynamin 1 assembled on lipid membrane has revealed that PH domain is tucked up into dynamin structure in apo state, but upon GTP binding, exposed toward membrane by a conformational change (Kong et al., 2018). In negatively stained electron micrographs, dynamin 1 is periodically arranged on the surface of MTs (La et al., 2020), suggesting a helical polymerization like in dynamin-membrane interaction (Zhang and Hinshaw, 2001). Therefore, PH domain including the putative-binding site PHDP5 is likely exposed toward MT surface. To examine whether PH domain of dynamin 1 can directly bind to MTs, immunofluorescence labeled MTs and glutathione transferase-tagged PH domain (GST-PH) were mixed and observed by confocal and electron microscopy (Figure 5—figure supplement 2). In confocal microscopic imaging, GST-PH co-localized with MTs, in contrast to controls, where MTs were mixed with GST alone (Figure 5—figure supplement 2A). These results were further confirmed in electron microscopic imaging, showing co-localizations of MTs and GST-PH (Figure 5—figure supplement 2B). Thus, dynamin 1 PH domain can associate with MTs, although it remains to be determined whether PHDP5 can directly bind to MTs.

Loading of PHDP5 (0.25 mM) alone in calyceal terminals had no effect on exo-endocytic capacitance changes, but when co-loaded with WT h-tau (20 µM), it significantly attenuated the h-tau-induced endocytic slowing (p < 0.05, Figure 5B). Scrambled PHDP5 peptide (0.25 mM) loaded as a control had no effect on h-tau-induced endocytic slowing. Like its effect on capacitance changes, intra-terminal infusion of PHDP5 alone (1 mM) did not affect EPSC amplitude, but when co-loaded with WT h-tau (20 µM), significantly attenuated the inhibitory effect of h-tau on EPSC amplitude (p < 0.01, Figure 5C). Co-infusion of scrambled PHDP5 (1 mM) with h-tau (20 µM) did not affect the h-tau-induced EPSC rundown (p = 0.46). These results further support that WT h-tau causes dynamin deficiency via new assembly of MTs thereby impairing SV endocytosis and synaptic transmission. These results also highlight PHDP5 as a potential therapeutic tool for rescuing synaptic dysfunctions associated with AD or Parkinson’s disease (PD).

Discussion

Using the calyx of Held in brainstem slices as an AD model for dissecting mammalian central excitatory synaptic transmission, we demonstrated that intra-terminal loading of WT h-tau impairs vesicle endocytosis and synaptic transmission via de novo MT assembly. Previous overexpression studies in cultured cells reported MT assembly by injection or overexpression of WT tau (Thies and Mandelkow, 2007; Drubin and Kirschner, 1986; Shemesh et al., 2008) or phosphorylated tau (Shahpasand et al., 2012; Liu et al., 2007). Compared with overexpression, our whole-cell method allows targeted loading of molecules in presynaptic terminals at defined concentrations because of a large pipette-to-cell volume ratio (Pusch and Neher, 1988). In postmortem brain tissue homogenates from AD patients, soluble tau content is estimated as 6 ng/µg of protein, which is eight times higher than controls (Khatooon et al., 1992). Assuming protein contents in brain homogenate as 10%, 60 kDa tau concentration in AD patients’ brain is estimated as 10 µM. Since elevation of soluble tau concentration likely occurs mainly in axons and axon terminal compartments of neurons, soluble tau concentration in AD patients in presynaptic terminals can be higher than that. Our results at the calyx of Held suggest that excitatory synaptic transmission, in general, can be significantly impaired in such situations.
fact, the magnitude of EPSC rundown after WT h-tau loading is comparable to that caused by the clinical dose of general anesthetic isoflurane at the calyx of Held in slice (Wang et al., 2020). In AD, tau pathology starts from the locus coeruleus in the brainstem and undergoes trans-synaptic propagation to hippocampal and neocortical neurons (Goedert et al., 2014). Present results in our model synapse suggest that synaptic functions in such tau-propagation pathways can be severely affected at the early stage of AD.

Figure 4. Wild-type (WT) human tau (h-tau) assembled microtubules (MTs) and increased bound-form dynamins in calyceal terminals. (A) Immunofluorescence images of brainstem slices showing loaded WT h-tau (green, left, arrowhead) labeled with anti h-tau/Alexa Fluor 488 antibodies (green, left panel), newly assembled MTs labeled with anti-β3-tubulin/Alexa Fluor 647 antibodies (magenta, middle), and increased bound-form dynamin labeled with anti-dynamin 1/Alexa Fluor 568 antibodies (red, right panel). (B) Bar graphs showing immunofluorescence intensities of h-tau (green), β3-tubulin (magenta), and dynamin (red) relative to controls with no loading (black bars). WT h-tau loading significantly increased β3-tubulin (p = 0.0105) and dynamin 1 (p = 0.0109) intensity in terminals compared to control terminals without WT h-tau loading (n = 5 terminals from 5 slices for each data set, two-tailed unpaired t-test with Welch’s correction; *p < 0.05, ***p < 0.001).

The online version of this article includes the following source data and figure supplement(s) for figure 4:

Source data 1. Raw immunofluorescence images from Figure 4A.

Source data 2. Data from Figure 4B.

Figure supplement 1. Super-resolution imaging of human tau (h-tau)-infused calyx of Held.

Figure supplement 1—source data 1. Raw images from Figure 4—figure supplement 1.

Figure supplement 2. Effects of a formin mDia inhibitor on synaptic vesicle (SV) endocytosis and tau infusion on the quantal EPSCs.

Figure supplement 2—source data 1. Data from Figure 4—figure supplement 2.
Figure 5. Dynamin 1 pleckstrin-homology (PH) domain peptide inhibited microtubule (MT)-dynamin 1 binding and prevented endocytic slowing and EPSC rundown caused by wild-type (WT) human tau (h-tau). (A) Top, partial amino acid sequence of PH domain of mouse dynamin 1 indicating the sequence of the synthetic dodecapeptide PHDP5 (560–571). Left, SDS-PAGE of MT-dynamin 1-binding assay. S, supernatant; P, precipitates. Dyn1, dynamin.
Figure 5 continued

1. Right, quantification of MT-dynamin 1 interaction. The bars indicate the percentage of dynamin 1 found in precipitates relative to total amount. PHDP5 significantly inhibited MT-dynamin 1 interaction (**p < 0.01, n = 3). (B) Presynaptic membrane capacitance records (superimposed) after loading h-tau alone (20 µM, red trace, taken from Figure 4B), h-tau co-loaded with DPHP5 (0.25 mM, blue) or scrambled DPHP5 (SDPHP5, green). DPHP5 alone (0.25 mM, black trace, 7 terminals from 7 slices) had no effect on capacitance changes compared to non-loading terminal controls (taken from Figure 3B). Bar graphs of endocytotic rates (middle panel) indicate significant difference (*p < 0.05, 7 terminals from 7 slices) between tau (red bar, 8 terminals from 8 slices) and DPHP5 + tau (blue, 7 terminals from 7 slices) as well as between SDPHP5 + tau (blue) and DPHP5 + tau (green, n = 6 terminals from 6 slices). The magnitudes of exocytotic capacitance changes were not significantly different between the groups, recorded 25 min after rupture. (C) DPHP5 attenuated h-tau-induced EPSC rundown. The EPSC rundown after h-tau infusion (20 µM, red dashed line; data taken from Figure 1A) was attenuated by DPHP5 (1 mM) co-loaded with h-tau (filled circles) but not by scrambled DPHP5 peptide (SDPHP5, open triangles, 1 mM). DPHP5 alone (1 mM, open circles) had no effect on EPSC amplitude throughout. Bar graphs indicate EPSC amplitude (normalized to that before infusion) 30 min after infusion. Significant difference (**p < 0.01) between tau and tau + DPHP5, between tau + DPHP5 and tau + SDPHP5. The difference between DPHP5 alone and DPHP5 + tau was not significant (p = 0.09), indicating the partial antagonistic effect of DPHP5 against h-tau-induced EPSC rundown.

The online version of this article includes the following source data and figure supplement(s) for figure 5:

Source data 1. Data from Figure 5A.
Source data 2. Data from Figure 5B and C.
Source data 3. Images from Figure 5A.
Figure supplement 1. PHDP5 strongly inhibited dynamin 1 binding to microtubules (MTs).
Figure supplement 1—source data 1. Images from Figure 5—figure supplement 1.
Figure supplement 1—source data 2. Data from Figure 5—figure supplement 1.
Figure supplement 2. Pleckstrin-homology (PH) domain of dynamin 1 directly binds to microtubules.
Figure supplement 2—source data 1. Images from Figure 5—figure supplement 2.

Membrane capacitance measurements at the calyx of Held revealed the primary target of WT h-tau toxicity as SV endocytosis. Endocytic slowing impairs SV recycling and reuse, thereby inhibiting SV exocytosis, particularly in response to high-frequency stimulations (Yamashita et al., 2005). The toxic effects of h-tau on SV endocytosis and synaptic transmission were prevented by nocodazole co-application. Together with the lack of toxicity of del-MTBD and toxic effects of taxol on synaptic transmission, these results suggest pathological roles of over-assembled MTs. Like WT h-tau, intra-terminal loading of WT α-synuclein slows SV endocytosis and impairs fidelity of high-frequency neurotransmission at the calyx of Held (Eguchi et al., 2017). α-Synuclein toxicities can be rescued by blocking MT assembly with nocodazole or a photosensitive colchicine derivative PST-1. Thus, a common mechanism likely underlies synaptic dysfunctions in AD and PD. Compared with α-synuclein, h-tau toxicity is much stronger on endocytosis as well as on synaptic transmission. Thus, abnormal elevation of endogenous molecules beyond homeostatic level may cause AD and PD symptoms, like many other human diseases.

Although the GTPase dynamin is a well-known player in endocytic fission of SVs (Hinshaw and Schmid, 1995; Takei et al., 1995), it was originally discovered as an MT-binding protein (Shpetner and Vallee, 1989). Subsequent studies indicated that this interaction upregulates dynamin’s GTPase activity (Maeda et al., 1992; Shpetner and Vallee, 1992) and can induce MT instability with dynamin 2 (Tanabe and Takei, 2009) or stabilizes MT bundle formation with dynamin 1 (La et al., 2020). However, the binding domain of dynamin remained unidentified. In this study, calyceal terminals loaded with WT h-tau showed a prominent increase in immunofluorescence signal intensity corresponding to bound dynamins. This was associated with an elevation in intra-terminal MTs, suggesting that newly assembled MTs induced by loaded h-tau sequestered cytosolic dynamins. These results well explain impairments of SV endocytosis by intra-terminal h-tau loading. Through synthetic peptide screening, we found that a dodecapeptide from dynamin 1 PH domain significantly inhibited the MT-dynamin interaction. This peptide PHDP5 is ~80% homologous to dynamin 3, another isoform involved in vesicle endocytosis (Raimondi et al., 2011). Although direct binding of this peptide to MTs remains to be seen, it significantly rescued endocytic impairments and EPSC rundown induced by intra-terminal WT h-tau. Hence, MTs over-assembled by soluble WT h-tau proteins likely sequester
free dynamins in presynaptic terminals, thereby blocking SV endocytosis and synaptic transmission, at least in this slice model. This dynamin sequestration mechanism by newly assembled MTs may also underlie the toxic effect of α-synuclein on SV endocytosis (Eguchi et al., 2017) in PD.

Unlike WT h-tau, the FTDP-linked mutant tau does not affect SV endocytosis (Zhou et al., 2017), but binds to both actin filaments (Fulga et al., 2007) and the SV transmembrane protein synaptogyrin (McInnes et al., 2018), thereby immobilizing SVs (McInnes et al., 2018; Zhou et al., 2017). WT-tau can also bind to synaptogyrin (McInnes et al., 2018), but cannot bind to F-actins because of a difference in the MT-binding regions between FTDP mutant and WT tau (Drubin and Kirschner, 1986; Roger et al., 2004). However, WT h-tau can bind to various other macromolecules and organelles such as MTs, neurofilaments, and ribosomes (Guo et al., 2017) as well as to synaptogyrin, thereby possibly immobilizing SVs. Recycling transport of SVs impaired by this mechanism might additionally contribute to the rundown of synaptic transmission remaining unblocked by the MT-dynamin blocker peptide.

In the absence of a powerful tool for alleviating symptoms associated with AD or PD, the calyx of Held slice model might provide a platform upon which therapeutic tools for rescuing synaptic dysfunctions can be pursued. The combination of this slice model with animal models could provide a new pathway toward rescuing neurological disorders.

Materials and methods

Animals

All experiments were performed in accordance with the guidelines of the Physiological Society of Japan and animal experiment regulations at Okinawa Institute of Science and Technology Graduate University.

Recombinant human tau preparation

Human tau (h-tau) lacking the MT-binding domain (amino acid 244–367, del-MTBD) were produced by site-directed mutagenesis as previously reported (Xie et al., 2014). Wild-type (WT) and del-MTBD mutant h-tau of 0N4R isoform were expressed in E. coli (BL21/DE3) and purified as described previously (Hasegawa et al., 1998) with minor modifications. Briefly, harvested bacteria expressing recombinant tau were lysed in homogenization buffer (50 mM PIPES, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, and 5 µg/ml Leupeptin, pH6.4), sonicated and centrifuged at 27,000× g for 15 min. Supernatants were charged onto phosphocellulose column (P11, Whatman). After washing with homogenization buffer containing 0.1 M NaCl, h-tau-containing fractions were eluted by the buffer containing 0.3 M NaCl. Subsequently, the proteins were precipitated by 50% saturated ammonium sulfate and re-dissolved in homogenization buffer containing 0.5 M NaCl and 1% 2-mercaptoethanol. After incubation at 100°C for 5 min, heatstable (soluble) fractions were obtained by centrifugation at 21,900× g, and fractionated by reverse phase high-performance liquid chromatography (RP-HPLC) using Cosmosyl Protein-R (Nacalai tesque Inc). Aliquots of h-tau containing fractions were lyophilized and stored at −80°C. Purified h-tau proteins were quantified by SDS-PAGE followed by Coomassie Brilliant Blue staining.

Purification of recombinant human dynamin 1 protein

His-tagged human dynamin 1 was expressed using the Bac-to-Bac baculovirus expression system (Thermo Fisher Scientific, Waltham, MA) and purified as described previously (Yamada et al., 2013). The purified dynamin solutions were concentrated using Centriplus YM50 (cat#4310; Merck-Millipore, Darmstadt, Germany).

MT polymerization assay

Effects of tau and nocodazole on MT polymerization were tested using a Tubulin Polymerization Assay (Cytoskeleton Inc, Denver, CO). Briefly, purified WT or del-MTBD mutant h-tau (10 µM) were mixed with porcine tubulin (20 µM) in an assembly buffer at 37°C. Nocodazole was added to the mixture at 0 min of incubation. MT polymerization was fluorometrically assayed (excitation at 360 nm, emission at 465 nm) using Infinit F-200 Microplate Reader (TECAN, Männedorf/Switzerland) at 1 min intervals for 30 min. After incubation, resultant solutions were subjected to centrifugation at 100,000× g for 15 min.
at 20°C. Supernatants (free tubulin fraction) and pellets (MT fraction) were subjected to SDS-PAGE to quantify the amount of tubulin assembled into MTs.

**Peptide synthesis and LC-MS/MS analysis**

The peptides were synthesized through conventional 9-fluorenylmethyloxycarbonyl (Fmoc) solid-phase peptide synthesis, onto preloaded Fmoc-alanine TCP-resins (Intavis Bioanalytical Instruments) using automated peptide synthesizer ResPep SL (Intavis Bioanalytical Instruments). All Fmoc-amino acids were purchased from Watanabe Chemical Industries and prepared at 0.5 M in N-methyl pyrrolidone (Wako Pure Chemical Industries). After synthesis, peptides were cleaved with (v/v/v) 92.5% TFA, 5% TIPS, and 2.5% water for 2 hr, precipitated using tert-butyl-methyl-ether at ~30°C, pelleted, and resuspended in water before lyophilization (EYELA FDS-1000) overnight. All synthesized peptides’ purity and sequence were then confirmed by LC-MS/MS using a Q-Exactive Plus Orbitrap hybrid mass spectrometer (Thermo Scientific) equipped with Ultimate 3000 nano-HPLC system (Dionex), HTC-PAL autosampler (CTC Analytics), and nanoelectrospray ion source.

**MT-dynamin-binding assay**

MT-binding assay was performed using Microtubule Binding Protein Spin Down Assay Kit (cat#BK029, Cytoskeleton Inc, Denver, CO). Briefly, 20 μl of 5 mg/ml tubulin in general tubulin buffer (GTB; 80 mM PIPES pH 7.0, 2 mM MgCl₂, 0.5 mM EGTA) supplemented with 1 mM GTP were polymerized by adding 2 μl of cushion buffer (80 mM PIPES pH 7.0, 1 mM MgCl₂, 1 mM EGTA, 60% glycerol) and incubated at 35°C for 20 min. MTs were stabilized with 20 μM Taxol. Taxol-stabilized MTs (2.5 μM) and dynamin 1 (1 μM) were incubated in GTB with or without 1 mM peptide at RT for 30 min. After incubation, the 50 μl of mixture was loaded on top of 100 μl cushion buffer supplemented with 20 μM Taxol, and then centrifuged at 100,000×g for 40 min at RT. After the ultracentrifugation, 50 μl of supernatant were taken and mixed with 10 μl of 5× sample buffer. The resultant pellet was resuspended with 50 μl of 1× sample buffer. Twenty μl of each sample was analyzed by SDS-PAGE and stained with SYPRO Orange. Protein bands were visualized using FLA-3000 (FUJIFILM Co. LTD, Tokyo, Japan).

**Immunocytochemical analysis**

The following primary antibodies were used: anti-β3-tubulin (Synaptic System, #302304), anti-h-tau (BioLegend, #806501), anti-dynamin (Invitrogen, PA1-660). Secondary antibodies were goat IgG conjugated with Alexa Fluor 488, 568, or 647 (Thermo Fisher Scientific). Acute brainstem slices (175 μm in thickness, see below) were fixed with 4% paraformaldehyde in PBS for 30 min at 37°C and overnight at 4°C. On the following day, slices were rinsed three times in PBS, permeabilized in PBS containing 0.5% Triton X-100 (Tx-100; Nacalai Tesque) for 30 min and blocked in PBS containing 3% bovine serum albumin (BSA; Sigma-Aldrich) and 0.05% Tx-100 for 45 min. Slices were incubated overnight at 4°C with primary antibody diluted in PBS 0.05% Tx-100, 0.3% BSA. On the next day, slices were rinsed three times with PBS containing 0.05% Tx-100 for 10 min and incubated with corresponding secondary antibody diluted in PBS 0.05% Tx-100, 0.3% BSA for 1 hr at RT. Slices were further rinsed three times in PBS 0.05% Tx-100 for 10 min and finally washed in PBS for another 10 min. Finally, slices were mounted on glass slides (Matsunami) using liquid mounting medium (Ibidi) and sealed using nail polish. Confocal images were acquired on laser scanning microscopes (LSM780 or LSM900, Carl Zeiss) equipped with a Plan-apochromat 63× oil immersion objective (1.4 NA) and 488, 561, and 633 nm excitation laser lines. For quantifying fluorescence intensity levels, the region of interest was delimited around calyceal terminals, and background fluorescence was subtracted using ImageJ software.

**Purification of GST-proteins**

The cDNA encoding PH domain (521–618 amino acids) of human dynamin 1 (NM_004408.4) (Gu et al., 2010) were prepared by PCR and subcloned into the plasmid pGEX-6P vector. The resulting plasmid was transformed into bacterial BL21(DE3) pLysS strain for protein expression. The expression of GST-fusion proteins was induced by 0.1 mM isopropyl-1-thio-D-galactopyranoside at 37°C for 3–6 hr in LB media supplemented with 100 μg/ml ampicillin at A₆₀₀ = 0.8. GST-fusion proteins were then purified as described (Slepnev et al., 2000). The nucleotide sequences of the constructs used in this study were verified with DNA sequence analysis. All the purified protein solutions (1–3 mg/ml) were stored at ~80°C and thawed at 37°C before use.
Microscopic observation of MT and GST-PH protein

GST or GST-PH was labeled using HiLyte Fluor-555 labeling kit according to manufacturer’s manual (cat#LK14, Dojindo Co. LTD, Kumamoto, Japan). HiLyte Fluor-555 labeled GST or GST-PH was mixed with non-labeled each protein at the ratio of 1:1.2. Flutax1-stabilized MTs (4.1 µM) and fluorescent GST or GST-PH at 11 µM were mixed in GTB containing 2 µM Flutax1 at 37°C for 60 min. Eight µl of the mixture was spotted on the slide glass and mounted with Fluoromount (cat#K024, Diagnostic BioSystems, Pleasanton, CA). Samples were examined using a spinning disc confocal microscope system (X-Light Confocal Imager; CREST OPTICS S.P.A., Rome, Italy) combined with an inverted microscope (IX-71; Olympus Optical Co., Ltd., Tokyo, Japan) and an iXon+ camera (Oxford Instruments, Oxfordshire, UK). The confocal system was controlled by MetaMorph software (Molecular Devices, Sunnyvale, CA). When necessary, images were processed using Adobe Photoshop CS3 or Illustrator CS3 software. For electron microscopic observation, samples were submitted to negative staining for imaging with a transmission electron microscope (H-7650, Hitachi High-Tech Corp., Tokyo, Japan) at 120 kV.

Slice electrophysiology

After killing C57BL/6N mice of either sex (P13–15) by decapitation under isoflurane anesthesia, brain-stems were isolated and transverse slices (175 µm thick) containing the medial nucleus of the trapezoid body (MNTB) were cut using a vibratome (VT1200S, Leica) in ice-cold artificial cerebrospinal fluid (aCSF, see below) with reduced Ca²⁺ (0.1 mM) and increased Mg²⁺ (3 mM) concentrations or sucrose-based aCSF (NaCl was replaced to 300 mM sucrose, concentrations of CaCl₂ and MgCl₂ was 0.1 and 6 mM, respectively). Slices were incubated for 1 hr at 36–37°C in standard aCSF containing (in mM): 125 NaCl, 2.5 KCl, 26 NaHCO₃, 1.25 NaHPO₄, 2 CaCl₂, 1 MgCl₂, 10 glucose, 3 myo-inositol, 2 sodium pyruvate, and 0.5 sodium ascorbate (pH 7.4 when bubbled with 95% O₂ and 5% CO₂, 310–320 mOsm), and maintained thereafter at RT (24–28°C).

Whole-cell recordings were made using a patch-clamp amplifier (Multiclamp 700A, Molecular Devices, Sunnyvale, CA, for pair recordings and EPC-10 USB, HEKA Elektronik, Germany, for presynaptic capacitance measurements) from the calyx of Held presynaptic terminals and postsynaptic MNTB principal neurons visually identified with a 60× or 40× water immersion objective (LUMPlanFL, Olympus) attached to an upright microscope (Axioskop2, Carl Zeiss, or BX51WI, Olympus, Japan). Data were acquired at a sampling rate of 50 kHz using pClamp (for Multiclamp 700A) or Patchmaster software (for EPC-10 USB) after online filtering at 5 kHz. The presynaptic pipette was pulled for the resistance of 7–10 MΩ and had a series resistance of 14–20 MΩ, which was compensated by 70% for its final value to be 7 MΩ. Resistance of the postsynaptic pipette was 5–7 MΩ, and its series resistance was 10–25 MΩ, which was compensated by up to 75% to a final value of 7 MΩ. The aCSF routinely contained picrotoxin (10 μM) and strychnine hydrochloride (0.5 μM) to block GABA A receptors and glycine receptors, respectively. Postsynaptic pipette solution contained (in mM): 130 CsCl, 5 EGTA, 1 MgCl₂, 10 glucose, 3 myo-inositol, 2 sodium pyruvate, and 0.5 sodium ascorbate (pH 7.4 when bubbled with 95% O₂ and 5% CO₂, 310–320 mOsm), and maintained thereafter at RT (24–28°C).

In simultaneous presynaptic and postsynaptic whole-cell recordings, postsynaptic MNTB neurons were voltage-clamped at the holding potential of −70 mV, and EPSCs were evoked, at 0.1 or 1 Hz, by action potentials elicited by a depolarizing current (1 ms) injected in calyceal terminals. For intraterminal loading of taxol (1 µM), it was diluted in presynaptic pipette solution from 5 mM DMSO stock for final DMSO concentration to be 0.02%. Likewise, nocodazole (20 µM, 0.1% DMSO) was included in presynaptic pipette solution. Presynaptic pipette solutions in nocodazole controls contained 0.1% DMSO. In simultaneous pre- and postsynaptic recordings, WT h-tau, del-MTBD tau, taxol, or synthetic peptides were loaded in calyceal terminals using the pipette perfusion technique (Hori et al., 1999; Hori and Takahashi, 2012). Briefly, a fine superfusion tube composed of plastic and glass tubes was installed in a presynaptic patch pipette. After backfilling the tube with pipette solutions containing synaptotagmin and/or peptides, it was inserted into a patch pipette with its tip 500–600 µm behind the tip of presynaptic patch pipette. After recording baseline EPSCs, the tube solution was delivered into presynaptic patch pipette with a positive pressure (8–10 psi) applied using a pico-pump. Membrane capacitance (C m) measurements were made from calyx of Held presynaptic terminals in the whole-cell configuration at RT (Sun and Wu, 2001; Yamashita et al., 2005). Calyceal terminals
were voltage-clamped at a holding potential of −80 mV, and a sinusoidal voltage command (1 kHz, 60 mV in peak-to-peak amplitude) was applied. To isolate presynaptic voltage-gated Ca²⁺ currents (ICa), the aCSF contained 10 mM tetraethylammonium chloride, 0.5 mM 4-aminopyridine, 1 µM tetrodotoxin, 10 µM bicuculline methiodide, and 0.5 µM strychnine hydrochloride. The presynaptic pipette solution contained (in mM): 125 Cs methanesulfonate, 30 CsCl, 10 HEPES, 0.5 EGTA, 12 disodium phosphocreatine, 3 MgATP, 1 MgCl₂, 0.3 Na₂GTP (pH 7.3 adjusted with CsOH, 315–320 mOsm). Tau or synthetic peptides were dissolved in pipette solution and backfilled into the pipette briefly after loading the tau-free pipette solution from the pipette tip. Care was taken to maintain series resistance <16 MΩ to allow dialysis of the terminal with pipette solution. Recording pipette tips were coated with dental wax to minimize stray capacitance (4–5 pF). Single square pulse (−80 to 10 mV, 20 ms duration) was used to induce presynaptic ICa. In these experiments, exocytic capacitance change (∆Cm) represents ~5 times larger number of SVs (estimated from ∆Cm divided by Cm of single SV) than that in the immediately releasable pool by presynaptic action potentials (estimated by the size of maximally evoked EPSCs divided by the size of miniature EPSCs). Membrane capacitance changes within 450 ms of square-pulse stimulation were excluded from analysis to avoid contamination by conductance-dependent capacitance artifacts (Yamashita et al., 2005). To avoid the influence of capacitance drift on baseline, we removed data when the baseline drift measured 0–10 s before stimulation was over 5 fF/s. When the drift was 1–5 fF/s, we subtracted a linear regression line of the baseline from the data for the baseline correction. The endocytic rate was calculated from the slope of the normalized Cm changes during the initial 10 s after the stimulation.

Data analysis and statistics
Data were analyzed using IGOR Pro 6 (WaveMatrics), Excel 2016 (Microsoft), and StatPlus (AnalystSoft Inc) and KaleidaGraph for Macintosh, version 4.1 (Synergy Software Inc, Essex Junction, VT). All values are given as mean ± SEM. Differences were considered statistically significant at p < 0.05 in paired or unpaired t-tests, one-way ANOVA with Scheffe post hoc test and repeated-measures two-way ANOVA with post hoc Scheffe test.

Study approval
All experiments were carried out in accordance with the regulation and guidelines of Okinawa Institute of Science and Technology Graduate University (Approval number: 2021-347-00).

Acknowledgements
We thank Yasuo Ihara, Nobuyuki Nukina, and Takeshi Sakaba for comments and Patrick Stoney for editing this paper. We also thank Shota Okuda and Mikako Matsubara for their contributions in the early stage of this study, and Satoko Wada-Kakuda for technical assistant with in vitro analysis of tau. This research was supported by funding from Okinawa Institute of Science and Technology and from Technology (OIST) and Core Research for the Evolutional Science and Technology of Japan Science and Technology Agency (CREST) to TT, and by Scientific Research on Innovative Areas to TM (Brain Protein Aging and Dementia Control 26117004).

Additional information

| Funder | Grant reference number | Author |
|--------|------------------------|--------|
| Okinawa Institute of Science and Technology Graduate University | | Tomoyuki Takahashi |
| Core Research for Evolutional Science and Technology | | Tomoyuki Takahashi |
Author contributions
Tetsuya Hori, Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing - original draft, Writing - review and editing; Kohgaku Eguchi, Han-Ying Wang, Satyajit Mahapatra, Formal analysis, Investigation, Visualization, Writing - review and editing; Tomohiro Miyasaka, Formal analysis, Funding acquisition, Investigation, Resources, Visualization, Writing - review and editing; Laurent Guillaud, Formal analysis, Investigation, Methodology, Visualization, Writing - review and editing; Zacharie Taoufiq, Formal analysis, Investigation, Resources, Visualization, Writing - review and editing; Hiroshi Yamada, Formal analysis, Investigation, Project administration, Resources, Supervision, Visualization, Writing - review and editing; Kohji Takei, Conceptualization, Investigation, Project administration, Resources, Supervision, Visualization, Writing - original draft, Writing - review and editing; Tomoyuki Takahashi, Conceptualization, Data curation, Project administration, Supervision, Visualization, Writing - original draft, Writing - review and editing

Author ORCIDs
Tetsuya Hori http://orcid.org/0000-0002-0823-3306
Kohgaku Eguchi http://orcid.org/0000-0002-6170-2546
Han-Ying Wang http://orcid.org/0000-0002-3021-7134
Laurent Guillaud http://orcid.org/0000-0002-9688-0991
Tomoyuki Takahashi http://orcid.org/0000-0002-8771-7666

Ethics
All experiments were performed in accordance with the guidelines of the Physiological Society of Japan and animal experiment regulations at Okinawa Institute of Science and Technology Graduate University.

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.73542.sa1
Author response https://doi.org/10.7554/eLife.73542.sa2

Additional files
Supplementary files
• Transparent reporting form

Data availability
All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for All Figures.

References
Ballatore C, Lee VM-Y, Trojanowski JQ. 2007. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nature Reviews. Neuroscience 8:663–672. DOI: https://doi.org/10.1038/nrn2194, PMID: 17684513
Bartolini F, Gundersen GG. 2010. Formins and microtubules. Biochimica et Biophysica Acta 1803:164–173. DOI: https://doi.org/10.1016/j.bbamcr.2009.07.006, PMID: 19631698
Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. 1993. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11:153–163. DOI: https://doi.org/10.1016/0896-6273(93)90279-z, PMID: 8393323
Binder LI, Frankfurter A, Rebhun Ll. 1985. The distribution of tau in the mammalian central nervous system. The Journal of Cell Biology 101:1371–1378. DOI: https://doi.org/10.1083/jcb.101.4.1371, PMID: 3930508
Brunden KR, Trojanowski JQ, Lee VM-Y. 2009. Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies. Nature Reviews. Drug Discovery 8:783–793. DOI: https://doi.org/10.1038/nrd2959, PMID: 19794442

de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pittick R, Sahara N, Ashe KH, Carlson GA, Spies-Jones TL, Hyman BT. 2012. Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 73:685–697. DOI: https://doi.org/10.1016/j.neuron.2011.11.033, PMID: 22365544

Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. 1992. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Molecular Biology of the Cell 3:1141–1154. DOI: https://doi.org/10.1091/mbc.3.10.1141, PMID: 1421571

Drubin DG, Kirschner MW. 1986. Tau protein function in living cells. The Journal of Cell Biology 103:2739–2746. DOI: https://doi.org/10.1083/jcb.103.6.2739, PMID: 3098742

Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E. 1998. Overexpression of tau proteins with FTDP-17 mutations has a reduced ability to assemble into rings suggesting a mechanism for coated vesicle budding. The Journal of Cell Biology 103:2739–2746. DOI: https://doi.org/10.1083/jcb.103.6.2739, PMID: 3098742

Eguchi K, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E. 1998. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer’s disease. The Journal of Cell Biology 143:777–794. DOI: https://doi.org/10.1083/jcb.143.3.777, PMID: 9813097

Eguchi K, Taoufiq Z, Thorn-Seshold O, Trauner D, Hasegawa M, Takahashi T. 2017. Wild-Type Monomeric α-Synuclein Can Impair Vesicle Endocytosis and Synaptic Fidelity via Tubulin Polymerization at the Calyx of Held. The Journal of Neuroscience 37:6043–6052. DOI: https://doi.org/10.1523/JNEUROSCI.0719-17.2017, PMID: 28576942

Fein JA, Sokolow S, Miller CA, Vinters HV, Yang F, Cole GM, Gulya KH. 2008. Co-localization of amyloid beta and tau pathology in Alzheimer’s disease synaptosomes. The American Journal of Pathology 172:1683–1692. DOI: https://doi.org/10.2353/apjpath.2008.070829, PMID: 18467692

Fulga TA, Elson-Siewab I, Khurana V, Osborn T, Reiser J, Pollak M, Hartwig J, Sever S. 2010. Direct dynamin-actin interactions regulate the actin cytoskeleton. The EMBO Journal 29:3593–3606. DOI: https://doi.org/10.1038/emboj.2010.249, PMID: 20935625

Guo T, Noble W, Hanger DP. 2017. Roles of tau protein in health and disease. Acta Neuropathologica 133:488–491. DOI: https://doi.org/10.1007/s00702-016-2074-3, PMID: 28576942

Hasegawa M, Smith MJ, Goedert M. 1998. Tau proteins with FTDP-17 mutations have a reduced ability to assemble into rings suggesting a mechanism for coated vesicle budding. Nature 374:190–192. DOI: https://doi.org/10.1038/374190a0, PMID: 8787694

Hori T, Takai Y, Takahashi T. 1999. Presynaptic mechanism for phorbol ester-induced synaptic potentiation. The Journal of Neuroscience 19:7262–7267. DOI: https://doi.org/10.1523/JNEUROSCI.0179-17.2017, PMID: 9813097

Hori T, Takai Y, Takahashi T. 1999. Presynaptic mechanism for phorbol ester-induced synaptic potentiation. The Journal of Neuroscience 19:7262–7267. DOI: https://doi.org/10.1523/JNEUROSCI.0179-17.2017, PMID: 9813097

Ittner LM, Fändrich M, Schonrock N. 2008. Is tau aggregation toxic or protective: a sensible question in the absence of sensitive methods? Journal of Neurochemistry and Neuroscience Reports 14:495. DOI: https://doi.org/10.1007/s11910-014-0495-z, PMID: 25218483

Ittner LM, Takahashi T. 2012. Kinetics of synaptic vesicle refilling with neurotransmitter glutamate. Neuron 76:511–517. DOI: https://doi.org/10.1016/j.neuron.2012.08.013, PMID: 23141063

Jang K, Lee VM-Y. 2011. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. The Journal of Biological Chemistry 286:15317–15331. DOI: https://doi.org/10.1074/jbc.M110.209296, PMID: 21372138

Karp S, Fan J, Smith MJ, Goedert M, Amos LA. 2003. Repeat motif of tau bind to the insides of microtubules in the absence of taxol. The EMBO Journal 22:70–77. DOI: https://doi.org/10.1093/emboj/cdg001, PMID: 12505985

Khatoon S, Grundke-Iqbal I, Iqbal K. 1992. Brain levels of microtubule-associated protein tau are elevated in Alzheimer’s disease: a radioimmuno-slot-blot assay for nanograms of the protein. Journal of Neurochemistry 59:750–753. DOI: https://doi.org/10.1011/j1.1471-4159.1992.tb09432.x, PMID: 1629745
Kong L, Sochacki KA, Wang H, Fang S, Canagarajah B, Kehr AD, Rice WJ, Strub M-P, Tarasova JW, Hinshaw JE. 2018. Cryo-EM of the dynamin polymer assembled on lipid membrane. *Nature* **560**:258–262. DOI: https://doi.org/10.1038/s41586-018-0378-6, PMID: 30069048

Koss DJ, Jones G, Cranston A, Gardner H, Kanaan NM, Platt B. 2016. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer’s disease and track disease progression and cognitive decline. *Acta Neuropathologica* **132**:875–895. DOI: https://doi.org/10.1007/s00401-016-1632-3, PMID: 2770234

Kubo A, Misonou H, Matsuyama M, Nomori A, Wada-Kakuda S, Takashima A, Kawata M, Murayama S, Ihara Y, Miyasaka T. 2019. Distribution of endogenous normal tau in the mouse brain. *The Journal of Comparative Neurology* **527**:985–998. DOI: https://doi.org/10.1002/cne.24577, PMID: 30408165

La TM, Tachibana H, Li S-A, Abe T, Seiriki S, Nagaoka H, Takashima E, Takeda T, Ogawa D, Makino S-I, Asanuma K, Watanabe M, Tian X, Ishibe S, Sakane A, Sasaki T, Wada J, Takei K, Yamada H. 2020. Dynamin 1 is important for microtubule organization and stabilization in glomerular podocytes. *FASEB Journal* **34**:16449–16463. DOI: https://doi.org/10.1096/fj.202001240RR, PMID: 33070431

Lee VM-Y, Brunden KR, Hutton M, Trojanowski JQ. 2011. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. *Cold Spring Harbor Perspectives in Medicine* 1:a006437. DOI: https://doi.org/10.1101/cshperspect.a006437, PMID: 2229117

Liu F, Li B, Tung E-J, Grundke-Iqbal I, Iqbal K, Gong C-X. 2007. Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. *The European Journal of Neuroscience* **26**:3429–3436. DOI: https://doi.org/10.1111/j.1460-9568.2007.05955.x, PMID: 18052981

Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. 2012. Trans-synaptic spread of tau pathology in vivo. *PLOS ONE* 7:e31302. DOI: https://doi.org/10.1371/journal.pone.0031302, PMID: 22312444

Maeda K, Nakata T, Noda Y, Sato-Yoshitake R, Hirokawa N. 1992. Interaction of dynamin with microtubules: its structure and GTPase activity investigated by using highly purified dynamin. *Molecular Biology of the Cell* **3**:1181–1194. DOI: https://doi.org/10.1091/mbc.3.10.1181, PMID: 1421574

Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, Miyasaka T, Murayama S, Ikai A, Takashima A. 2007. Granular tau oligomers as intermediates of tau filament formation. *Biochemistry* **46**:3856–3861. DOI: https://doi.org/10.1021/bi61359o, PMID: 17338548

McInnes J, Wierda K, Snellins A, Bounti L, Wang Y-C, Stanciu I-C, Apóstolo N, Gevaert K, Dewachter I, McInnes J, Maeda S. 2011. The many faces of tau. *Acta Neuropathologica* **127**:257–270. DOI: https://doi.org/10.1007/s00401-013-1215-5, PMID: 24938363

Morris M, Maeda S, Vossel K, Mucke L. 2011. The many faces of tau. *Neuron* **70**:410–426. DOI: https://doi.org/10.1016/j.neuron.2011.04.009, PMID: 21555069

Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A, Drummond JA, Berg S, MacKay D, Asuni AA, Bhat R, Lovestone S. 2004. GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. *Molecular Psychiatry* **9**:522–530. DOI: https://doi.org/10.1038/sj.mp.4001483, PMID: 14993907

Piriy Ananda Babu L, Wang H-Y, Eguchi K, Guillaud L, Takahashi T. 2020. Microtubule and Actin Differentially Regulate Synaptic Vesicle Cycling to Maintain High-Frequency Neurotransmission. *The Journal of Neuroscience* **40**:131–142. DOI: https://doi.org/10.1523/JNEUROSCI.1571-19.2019, PMID: 31767677

Polydoro M, Dzhala VI, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, Pitstick R, Carlson GA, Staley KJ, Spires-Jones TL, Hyman BT. 2014. Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer’s disease model. *Acta Neuropathologica* **127**:257–270. DOI: https://doi.org/10.1007/s00401-013-1215-5, PMID: 24271788

Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP. 2013. Physiological release of endogenous tau is stimulated by neuronal activity. *EMBO Reports* **14**:389–394. DOI: https://doi.org/10.1038/embr.2013.15, PMID: 23412472

Pusch M, Neher E. 1988. Rates of diffusional exchange between small cells and a measuring patch pipette. *Pflugers Archiv* **411**:204–211. DOI: https://doi.org/10.1007/BF00582316, PMID: 2451806

Raimondi A, Ferguson SM, Lou X, Armbruster M, Paradise S, Giovedi S, Messa M, Kono N, Takasaki J, Cappello V, O’Toole E, Ryan TA, De Camilli P. 2011. Overlapping role of dynamin isoforms in synaptic vesicle endocytosis. *Neuron* **70**:1100–1114. DOI: https://doi.org/10.1016/j.neuron.2011.04.031, PMID: 21689597

Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu G-Q, Mucke L. 2007. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. *Science (New York, N.Y.)* **316**:750–754. DOI: https://doi.org/10.1126/science.1141736, PMID: 17478722

Rogers B, Al-Bassam J, Dehmelt L, Milligan RA, Haldane S. 2004. MAP2c, not tau, binds and bundles F-actin via its microtubule binding domain. *Current Biology* **14**:363–371. DOI: https://doi.org/10.1016/j.cub.2004.01.058, PMID: 15028210

Sakata T, Kononenko NL, Bacetic J, Pechstein A, Schmoranz J, Yao L, Barth H, Shupliakov O, Kobler O, Aktories K, Haucke V. 2013. Fast neurotransmitter release regulated by the endocytic scaffold intersectin. *PNAS* **110**:6266–6271. DOI: https://doi.org/10.1073/pnas.1219234110, PMID: 2363571

Santacruz K, Lewis J, Spikes T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. *Science (New York, N.Y.)* **309**:476–481. DOI: https://doi.org/10.1126/science.1113694, PMID: 16020737
Slepnev VI, Shpetner HS. 1992. Dynamin is a GTPase stimulated to high levels of activity by microtubules.

Shpetner HS, Vallee RB. 1989. Identification of dynamin, a novel mechanochemical enzyme that mediates interactions between microtubules.

Cell 59:421–432. DOI: https://doi.org/10.1016/0092-8674(89)90027-5, PMID: 2529977

Shpetner HS, Vallee RB. 1992. Dynamin is a GTPase stimulated to high levels of activity by microtubules. Nature 355:733–735. DOI: https://doi.org/10.1038/355733a0, PMID: 1311055

Slepnev VI, Ochoa GC, Butler MH, De Camilli P. 2000. Tandem arrangement of the clathrin and AP-2 binding domains in amphiphysin 1 and disruption of clathrin coat function by amphiphysin fragments comprising these sites. The Journal of Biological Chemistry 275:17583–17589. DOI: https://doi.org/10.1074/jbc.M910430199, PMID: 10748223

Seykhan T, Kaempf N, Sakaba T, Vollweiler D, Goedeler F, Puchkov D, Kononenko NL, Haucke V. 2017. Synaptic Vesicle Endocytosis Occurs on Multiple Timescales and Is Mediated by Formin-Dependent Actin Assembly. Neuron 93:854–866. DOI: https://doi.org/10.1016/j.neuron.2017.02.011, PMID: 28231467

Shimizu M, Goedert M. 2013. Tau pathology and neurodegeneration. The Lancet. Neurology 12:609–622. DOI: https://doi.org/10.1016/S1474-4422(13)70090-5, PMID: 23684085

Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. 2002. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. The Journal of Cell Biology 156:1051–1063. DOI: https://doi.org/10.1083/jcb.200108057, PMID: 11901170

Sun JY, Wu LG. 2001. Fast kinetics of exocytosis revealed by simultaneous measurements of presynaptic capacitance and post synaptic currents at a central synapse. Neuron 30:171–182. DOI: https://doi.org/10.1016/s0896-6273(01)00271-9, PMID: 11343653

Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexlert D, Zhou L, Rune G, Mandelkow E, D’Hooge R, Alzheimer C, Mandelkow E-M. 2011. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. The Journal of Neuroscience 31:2511–2525. DOI: https://doi.org/10.1523/JNEUROSCI.3684-11.2012, PMID: 21325519

Tai H-C, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. 2012. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. The American Journal of Pathology 181:1426–1435. DOI: https://doi.org/10.1016/j.ajpath.2012.06.033, PMID: 22867111

Takahashi T, Hori T, Nakamura Y, Yamashita T. 2012. Patch-Clamp Recording Method in Slices for Studying Presynaptic Mechanisms. Okada Yasunobu (Ed). Patch Clamp Techniques. Springer Tokyo. p. 137–145. DOI: https://doi.org/10.1007/978-4-431-53993-3

Takami C, Eguchi K, Hori T, Takahashi T. 2017. Impact of vesicular glutamate leakage on synaptic transmission at the calyx of Held. The Journal of Physiology 595:1263–1271. DOI: https://doi.org/10.1113/JP273467, PMID: 27801801

Takei K, McPherson PS, Schmid SL, De Camilli P. 1995. Tubular membrane invaginations coated by dynamin rings are induced by GTP-gamma S in nerve terminals. Nature 374:186–190. DOI: https://doi.org/10.1038/374186a0, PMID: 7877693

Tanabe K, Takei K. 2009. Dynamic instability of microtubules requires dynamin 2 and is impaired in a Charcot-Marie-Tooth mutant. The Journal of Cell Biology 185:939–948. DOI: https://doi.org/10.1083/jcb.200803153, PMID: 19528294

Thies E, Mandelkow EM. 2007. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. The Journal of Neuroscience 27:2896–2907. DOI: https://doi.org/10.1523/JNEUROSCI.4647-06.2007, PMID: 17360912

Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkelbeiner S, Cui B, Mucke L. 2010. Tau reduction prevents Abeta-induced defects in axonal transport. Science (New York, N.Y.) 330:198. DOI: https://doi.org/10.1126/science.1194653, PMID: 20829454

Wang HY, Eguchi K, Yamashita T, Takahashi T. 2020. Frequency-Dependent Block of Excitatory Neurotransmission by Isoflurane via Dual Presynaptic Mechanisms. The Journal of Neuroscience 40:4103–4115. DOI: https://doi.org/10.1523/JNEUROSCI.2946-19.2020, PMID: 32327530

Watanabe S, Mamer LE, Raychaudhuri S, Luvsanjav D, Eisen J, Trimbach T, Sohl-Kielczynski B, Fenske P, Milosievic I, Rosenmund C, Jorgensen EM. 2018. Synaptotagmin and Endophilin Mediate Neck Formation during Ultrafast Endocytosis. Neuron 98:1184–1197. DOI: https://doi.org/10.1016/j.neuron.2018.06.005, PMID: 29953872

Xie C, Miyasaka T, Yoshimura S, Hatsuta H, Yoshina S, Kage-Nakadai E, Mitanis S, Murayama S, Ichara Y. 2014. The homologous carboxyl-terminal domains of microtubule-associated protein 2 and TAU induce neuronal dysfunction and have differential fates in the evolution of neurofibillary tangles. PLOS ONE 9:e89796. DOI: https://doi.org/10.1371/journal.pone.0089796, PMID: 24587039

Hori et al. eLife 2022;11:e73542. DOI: https://doi.org/10.7554/eLife.73542
Yamada H, Abe T, Satch A, Okazaki N, Tago S, Kobayashi K, Yoshida Y, Oda Y, Watanabe M, Tomizawa K, Matsu H, Takei K. 2013. Stabilization of actin bundles by a dynamin 1/cortactin ring complex is necessary for growth cone filopodia. The Journal of Neuroscience 33:4514–4526. DOI: https://doi.org/10.1523/JNEUROSCI.2762-12.2013, PMID: 23467367

Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgräfe K, Mandelkow E-M, Holtzman DM. 2014. Neuronal activity regulates extracellular tau in vivo. The Journal of Experimental Medicine 211:387–393. DOI: https://doi.org/10.1084/jem.20131685, PMID: 24534188

Yamashita T, Hige T, Takahashi T. 2005. Vesicle endocytosis requires dynamin-dependent GTP hydrolysis at a fast CNS synapse. Science (New York, N.Y.) 307:124–127. DOI: https://doi.org/10.1126/science.1103631, PMID: 15637282

Yoshida H, Ihara Y. 1993. Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau. Journal of Neurochemistry 61:1183–1186. DOI: https://doi.org/10.1111/j.1471-4159.1993.tb03642.x, PMID: 8360683

Yoshiyama Y, Higuchi M, Zhang B, Huang S-M, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM-Y. 2007. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337–351. DOI: https://doi.org/10.1016/j.neuron.2007.01.010, PMID: 17270732

Yuan A, Kumar A, Peterhoff C, Duff K, Nixon RA. 2008. Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. The Journal of Neuroscience 28:1682–1687. DOI: https://doi.org/10.1523/JNEUROSCI.5242-07.2008, PMID: 18272688

Zhang P, Hinshaw JE. 2001. Three-dimensional reconstruction of dynamin in the constricted state. Nature Cell Biology 3:922–926. DOI: https://doi.org/10.1038/ncb1001-922, PMID: 11584275

Zhou L, McInnes J, Wierda K, Holt M, Herrmann AG, Jackson RJ, Wang Y-C, Swerts J, Beyens J, Miskiewicz K, Vilain S, Dewachter I, Moechats D, De Strooper B, Spires-Jones TL, De Wit J, Verstreken P. 2017. Tau association with synaptic vesicles causes presynaptic dysfunction. Nature Communications 8:15295. DOI: https://doi.org/10.1038/ncomms15295, PMID: 28492240